Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.35 |
| ▸ | RELA | Q04206 | 3/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7922248 | 0.81 | PIK3CD (0.47) | CTSKCA1CA2CA7APLNR | |
| SCHEMBL14831297 | 0.78 | CA1 (0.43) | CTSKCA1CA2CA7APLNR | |
| SCHEMBL12691730 | 0.76 | CA1 (0.42) | CTSKCA1CA2CA7APLNR | |
| SCHEMBL28382751 | 0.76 | CA1 (0.42) | CTSKCA1CA2CA7APLNR | |
| SCHEMBL16855012 | 0.75 | APLNR (0.42) | CTSKCA1CA2CA7APLNR | |
| SCHEMBL27277682 | 0.75 | APLNR (0.42) | CTSKCA1CA2CA7APLNR | |
| SCHEMBL21258185 | 0.74 | CA1 (0.41) | CTSKCA1CA2CA7APLNR | |
| SCHEMBL22728175 | 0.74 | CA1 (0.41) | CTSKCA1CA2CA7APLNR | |
| SCHEMBL17035395 | 0.74 | MEN1 (0.43) | CTSKCA1CA2CA7APLNR | |
| SCHEMBL28467923 | 0.74 | CTSK (0.51) | CTSKCA1CA2CA7APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135577-A1 | DIHYDROPYRAZOLOPYRAZINONE DERIVATIVE HAVING MGAT2 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2022-05-05 | — | — | US | disclosed |
| WO-2012000608-A2 | NOVEL BETA-AMINOALDEHYDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR CHEMICAL USE AS REACTIVE INTERMEDIATES | GLUESENKAMP KARL-HEINZ (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135577-A1 | DIHYDROPYRAZOLOPYRAZINONE DERIVATIVE HAVING MGAT2 INHIBITORY ACTIVITY | MGAT2, MGAT1, SLC6A5 | CTSK 2341/4885CA1 3415/4885CA2 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.